Navigation Links
GenVec Achieves Second Milestone in Collaboration
Date:12/6/2011

GAITHERSBURG, Md., Dec. 6, 2011 /PRNewswire/ -- GenVec, Inc. (Nasdaq: GNVC) today announced that it has achieved the second milestone in its collaboration with Novartis (NYSE: NVS), related to the development of treatments for hearing loss and balance disorders. The milestone was triggered by the successful completion of certain preclinical development activities.

"Completing this milestone reflects sustained progress and we look forward to reaching additional milestones with Novartis in this very exciting program," said Dr. Paul Fischer, GenVec's President and Chief Executive Officer.

About the CollaborationIn January 2010, GenVec entered into a worldwide licensing and collaboration agreement with Novartis to discover and develop novel treatments for hearing loss and balance disorders. Under the terms of the agreement, if certain clinical, regulatory, and sales milestones are met, GenVec is eligible to receive up to $213.6 million, including upfront and milestone payments in addition to royalties on future sales.

In August 2010, we entered into an additional agreement with Novartis, to manufacture clinical trial material for up to two lead product candidates for this program.

About GenVecGenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss a
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
2. GenVec Expands Contract Supporting Malaria Vaccine Program
3. GenVec Reports Second Quarter 2009 Financial Results
4. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
5. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
6. GenVec Announces Third Quarter 2009 Results Conference Call
7. GenVec Reports Third Quarter 2009 Financial Results
8. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
9. GenVec to Present at the 13th Annual BIO CEO & Investor Conference
10. GenVec To Host Fourth Quarter and Year-End 2010 Earnings Call and Webcast
11. GenVec, Inc. Announces Effectiveness of Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 Research and Markets ... Biology Market 2014-2018" report to their offering. ... term synthetic biology covers the designing and engineering of ... as the redesigning of natural biological systems that provide ... a form of extreme genetic engineering because it not ...
(Date:7/28/2014)... NEW YORK , July 28, 2014 /PRNewswire/ ... for ConvergeHEALTH by Deloitte , has been ... Data Interchange Standards Consortium, a non-profit working to ... research data, particularly as it relates to electronic ... to continue CDISC,s mission of collaborating with organizations ...
(Date:7/28/2014)... July 28, 2014 Appistry, Inc. ... that bring the power of genomics to next-generation medicine, ... Appistry Pipeline Challenge . , Two Appistry staff ... the National Center for Genome Resources, and Mr. Neil ... Clinics of Kansas City. Rounding out the panel are ...
(Date:7/28/2014)...  InterMune, Inc. (NASDAQ: ITMN ) today ... financial results at the close of the U.S. markets ... webcast will be hosted by InterMune at 4:30 p.m. ... and others may participate in the conference call by ... replay of the webcast and teleconference will be available ...
Breaking Biology Technology:Global Synthetic Biology Market 2014-2018 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Appistry Names Industry Experts from the National Center for Genome Resources and Mercy Children's, Kansas City, to Judge Pipeline Challenge Competition 2InterMune to Release Second Quarter Financial Results on August 6 2
... 3, 2011 MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ... March 31, 2011. The net income for the ... to a net loss of $14.1 million during the same ... March 31, 2011 was related primarily to the $34.2 million ...
... May 2, 2011 Anadys Pharmaceuticals, Inc. (Nasdaq: ... 2011 financial results on Thursday, May 5, 2011, after the ... conference call and webcast on Thursday, May 5, 2011 at ... 2011 financial results and highlights and to provide an update ...
... WAGENINGEN, Netherlands, May 2, 2011 Dyadic International, ... company focused on the discovery, development, manufacture and ... biopharmaceutical, biofuels and industrial enzyme industries, announced today ... B.V. ("Dyadic Netherlands"), has entered into a research ...
Cached Biology Technology:MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 2MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 3MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 4MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results 5Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results 2Dyadic Netherlands Enters Into R&D Collaboration With Sanofi Pasteur and EnGen Bio 2
(Date:7/29/2014)... news for parents of preterm babies latest research from ... time they become teenagers, the brains of many preterm children ... , A study conducted by the University,s Robinson Research ... child experiences no brain injury in early life, their cognitive ... their term-born peers. , However, the results of the study, ...
(Date:7/28/2014)... drugs already approved by the U.S. Food and Drug ... growth of certain bacterial pathogens inside human cells, including ... fever. The findings, published in mBio , the ... demonstrate a new way of identifying non-antibiotic drugs that ... A handful of drugs on the list inhibit the ...
(Date:7/28/2014)... TEMPE, Ariz. - Reactions among minerals and organic compounds ... deep carbon cycle, they provide energy for the deep ... life. However, very little is known about how minerals ... Arizona State University have demonstrated how a common mineral ... negating the need for toxic solvents or expensive ...
Breaking Biology News(10 mins):Preterm children's brains can catch up years later 2New route to identify drugs that can fight bacterial infections 2Mineral magic? Common mineral capable of making and breaking bonds 2Mineral magic? Common mineral capable of making and breaking bonds 3
... Springer will publish The HUGO Journal in cooperation ... Springer as Genomic Medicine, The HUGO Journal has ... Members of HUGO will receive free access to the ... discounted rates. The HUGO Journal will focus ...
... announced today that its Ewell Sale Stewart Library has ... Heritage Library. The BHL is a group of 12 ... worldwide dedicated to digitizing the published literature on biodiversity ... more widely available. Scanning and cataloguing the materials preserves ...
... New evidence for ice-free summers with intermittent winter sea ... a period of greenhouse conditions - gives a glimpse of ... warming. Records of past environmental change in the Arctic ... period between 100 and 65 million years ago leading up ...
Cached Biology News:Academy Library accepted to prestigious Biodiversity Heritage Library 2Arctic climate under greenhouse conditions in the Late Cretaceous 2Arctic climate under greenhouse conditions in the Late Cretaceous 3
... serum biomarker chip to profile the relative ... chip containing 120 human cancer serum biomarker-specific ... discovery scientists to study panels of biomarkers ... and the likelihood of recurrence of cancer. ...
... is a highly sensitive reagent for the ... a purified form of recombinant E. coli ... which is sensitive to changes in its ... Phosphate Sensor is rapid and tight (Kd ...
... fume hood ventilates and purifies ... release of exhaust. Bonded charcoal ... Configurations are available with vertical ... final HEPA filter, work bench ...
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation,of endotoxins for research purposes....
Biology Products: